Brequinar, a DHODH inhibitor, serves as a potential agent to treat GPX4low cancers by triggering ferroptosis,134 whereas combined administration of brequinar and sulfasalazine synergistically suppresses GPX4high tumors growth.134 Moreover, AMPK activation enhances the assembly of pyrimidinosomes, rendering cancer cells more reliant on DHODH-mediated ferroptosis defense to counteract AMPK-associated stresses.458 The combination of brequinar and AMPK activators exhibit synergistic efficacy in tumor suppression through ferroptosis.458. The gene discussed is DHODH; the disease is neoplasm.